Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	287.85	11.29	14.69	9.6	34.89
Short-Term Investments	30.28	140.23	24.79	31.82	-
Cash & Short-Term Investments	318.13	151.52	39.49	41.42	34.89
Cash Growth	109.96%	283.70%	-4.67%	18.74%	6.79%
Accounts Receivable	0.06	10.37	10.37	0.55	0.39
Other Current Assets	4.75	1.5	1	0.92	1.16
Total Current Assets	322.94	163.39	50.86	42.89	36.44
Net Property, Plant & Equipment	31.85	6.87	7.61	6.94	4.62
Other Long-Term Assets	1.16	0.22	0.27	0.27	0.28
Total Assets	355.95	170.48	58.73	50.09	41.33
Accounts Payable	1.65	3.28	6.25	4.92	3.72
Accrued Expenses	15.56	4.91	-	-	-
Current Portion of Leases	0.2	0.83	0.75	0.68	0.42
Unearned Revenue	12	12	24.27	17.98	-
Other Current Liabilities	6.42	-	-	-	-
Total Current Liabilities	35.84	21.03	31.27	23.59	4.13
Long-Term Leases	14.32	0.62	1.49	1.88	2.45
Other Long-Term Liabilities	-	3.38	3.38	12.84	3.38
Total Long-Term Liabilities	14.32	3.99	4.86	14.72	5.83
Total Liabilities	50.16	25.02	36.13	38.31	9.96
Common Stock	0.06	0.05	0.03	0.03	0.02
Additional Paid-in Capital	610.33	344.22	181.7	148.74	139.4
Accumulated Other Comprehensive Income	0.28	1.03	0.24	0.11	-
Retained Earnings	-	-	-159.37	-137.08	-108.06
Shareholders' Equity	305.79	145.46	22.6	11.79	31.37
Total Liabilities & Equity	355.95	170.48	58.73	50.09	41.33
Total Debt	14.52	1.45	2.24	2.56	2.87
Net Cash (Debt)	303.61	150.06	37.25	38.86	32.01
Net Cash Growth	102.32%	302.84%	-4.14%	21.38%	-1.03%
Net Cash Per Share	6.53	4.26	1.39	1.58	1.39
Book Value	305.79	145.46	22.6	11.79	31.37
Book Value Per Share	6.58	4.13	0.84	0.48	1.36
Tangible Book Value	305.79	145.46	22.6	11.79	31.37
Tangible Book Value Per Share	6.58	4.13	0.84	0.48	1.36

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q